Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIGF-1 QD for Short Stature in Primary IGF-1 Deficiency
NCT00125190Phase 3Completed
- Sponsor
- Ipsen
- Start
- Jul 2005
- Primary completion
- Jan 2009
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mecasermin in primary insulin-like growth factor-1 deficiency (PIGFD), sponsored by Ipsen. Primary endpoints: Height Velocity From Pretreatment to Week 34 and Height Velocity From Week 34 to 86 at 86 weeks. Started Jul 2005; status: completed.
02
Drugs
mecasermin
03
Conditions
primary insulin-like growth factor-1 deficiency (PIGFD)
Beyond the preview
Go deeper on NCT00125190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125190.